Evidence map›Paper›PMID 24348987›Full record

ArticlePloS one2013

Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling.

Kevin J Ashcroft, Farhatullah Syed, Ardeshir Bayat

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. The Therapeutic Role of Genistein in Perimenopausal and Postmenopausal Women.The Journal of clinical and aesthetic dermatology · 2024
    Review
  6. Article
  7. Article
  8. HMedComm · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Defining a Unique Gene Expression Profile in Mature and Developing Keloids.JID innovations : skin science from molecules to population health · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Inhibition Effect ofClinical, cosmetic and investigational dermatology · 2023
    Article
  19. Article
  20. [Research advances on the characteristics of fibroblast in keloid].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kevin J AshcroftPlastic & Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, United Kingdom ; Institute of Inflammation & Repair, University of Manchester, Manchester, United Kingdom.
Farhatullah SyedPlastic & Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, United Kingdom ; Institute of Inflammation & Repair, University of Manchester, Manchester, United Kingdom.
Ardeshir BayatPlastic & Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, United Kingdom ; Institute of Inflammation & Repair, University of Manchester, Manchester, United Kingdom ; Department of Plastic and Reconstructive Surgery, University Hospital South Manchester Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom ; The University of Manchester, Manchester Academic Health Science Centre, University Hospital South Manchester Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom.
University of Manchester · GBWythenshawe Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Keloid disease (KD) is an abnormal cutaneous fibroproliferative disorder of unknown aetiopathogenesis. Keloid fibroblasts (KF) are implicated as mediators of elevated extracellular matrix deposition. Aberrant secretory behaviour by KF relative to normal skin fibroblasts (NF) may influence the disease state. To date, no previous reports exist on the ability of site-specific KF to induce fibrotic-like phenotypic changes in NF or normal scar fibroblasts (NS) by paracrine mechanisms. Therefore, the aim of this study was to investigate the influence of conditioned media from site-specific KF on the cellular and molecular behaviour of both NF and NS enabled by paracrine mechanisms. Conditioned media was collected from cultured primary fibroblasts during a proliferative log phase of growth including: NF, NS, peri-lesional keloid fibroblasts (PKF) and intra-lesional keloid fibroblasts (IKF). Conditioned media was used to grow NF, NS, PKF and IKF cells over 240 hrs. Cellular behavior was monitored through real time cell analysis (RTCA), proliferation rates and migration in a scratch wound assay. Fibrosis-associated marker expression was determined at both protein and gene level. PKF conditioned media treatment of both NF and NS elicited enhanced cell proliferation, spreading and viability as measured in real time over 240 hrs versus control conditioned media. Following PKF and IKF media treatments up to 240 hrs, both NF and NS showed significantly elevated proliferation rates (p<0.03) and migration in a scratch wound assay (p<0.04). Concomitant up-regulation of collagen I, fibronectin, α-SMA, PAI-1, TGF-β and CTGF (p<0.03) protein expression were also observed. Corresponding qRT-PCR analysis supported these findings (P<0.03). In all cases, conditioned media from growing marginal PKF elicited the strongest effects. In conclusion, primary NF and NS cells treated with PKF or IKF conditioned media exhibit enhanced expression of fibrosis-associated molecular markers and increased cellular activity as a result of keloid fibroblast-derived paracrine factors.

Indexed as

AdultAgedBlotting, WesternCell ProliferationCells, CulturedCell SurvivalCicatrixCulture Media, ConditionedFemaleFibroblastsHumansKeloidMaleMiddle AgedReverse Transcriptase Polymerase Chain ReactionSkinCulture Media, Conditioned

Identifiers

PMID24348987
PMCPMC3857170
OpenAlexW2084070887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.